Reply to: "Revisiting the estimation of hepatitis D global prevalence"
- PMID: 32863046
- DOI: 10.1016/j.jhep.2020.06.039
Reply to: "Revisiting the estimation of hepatitis D global prevalence"
Conflict of interest statement
Conflict of interest AMG reports personal payments and consulting honoraria from Roche Pharma Research & Early Development, Gilead, Janssen, and ViiV, and research funding from Roche Pharma Research & Early Development, Gilead, Janssen and ViiV, outside of the submitted work. Other authors do not declare any conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.J Hepatol. 2020 Sep;73(3):523-532. doi: 10.1016/j.jhep.2020.04.008. Epub 2020 Apr 23. J Hepatol. 2020. PMID: 32335166 Free PMC article.
-
Revisiting the estimation of hepatitis D global prevalence.J Hepatol. 2020 Nov;73(5):1279-1280. doi: 10.1016/j.jhep.2020.05.019. Epub 2020 Aug 21. J Hepatol. 2020. PMID: 32829929 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources